EL7.AI
StocksMedium•16 November 2026•
3 min read

Nuo Therapeutics’ Q3 2026 Revenue Rises to $1,866,125

Key Facts

1Nuo Therapeutics’ revenue in the third quarter of 2026 was $1,866,125, compared with $1,032,096 a year earlier.
2Product revenue rose to about $1,780,000 from $957,000, an increase of 86%.
3The company ended September 2026 with about $0.1 million in cash and about $2.5 million in current liabilities.
4The company estimated that thrombin supplies would return in the second quarter of 2027, following a temporary stockout of about two weeks in August 2026.

Nuo Therapeutics reported total revenue of $1,866,125 for the three months ended September 30, 2026, compared with $1,032,096 in the same period of 2025, according to its quarterly filing with the U.S. Securities and Exchange Commission. The increase was driven mainly by higher revenue from its Aurix product as its customer base expanded, alongside sales of centrifuge devices and kits tied to its agreement with Smith+Nephew. Product revenue rose to about $1,780,000 from about $957,000, an increase of about 86%. Distribution fees also contributed to total revenue, the company said. The results show commercial activity expanding during the quarter, while losses and limited liquidity remained key factors in the company’s financial position.

Gross profit rose to about $1,193,000 in the third quarter from about $625,000 a year earlier, while the gross margin increased to about 64% from 61%. The company, however, reported a net loss of $424,928, down from a loss of $537,919 in the corresponding quarter of 2025. Basic and diluted loss per share remained at $0.01 in both periods. This reflects an improvement in the net loss alongside sales growth and a wider margin, without the company returning to profitability. Operating activities used $1,215,351 in cash during the first nine months of 2026, compared with $442,325 in the same period a year earlier.

Nuo said revenue growth was driven mainly by higher Aurix revenue as its customer base expanded over the past year, as well as revenue from Smith+Nephew products related to centrifuge devices and kits. Under the agreement, the company supplies Smith+Nephew with a private-label version of Aurix in the United States, while retaining the ability to market and sell the product under its own brand. Nuo received a $250,000 milestone payment from Smith+Nephew in August 2026. Aurix is the company’s main commercial product: a point-of-care system used to process a patient’s blood and produce platelet-rich plasma for the treatment of chronic wounds. The system received U.S. Food and Drug Administration marketing clearance in 2007.

The company reported, however, that its cash balance was about $0.1 million as of September 30, 2026, against current liabilities of about $2.5 million. In its filing, it said ongoing losses and limited cash resources raise substantial doubt about its ability to continue as a going concern. Operating cash use worsened in the first nine months compared with the corresponding period, according to figures in the filing. These indicators put revenue growth and margin improvement in the context of tight liquidity. The filing did not provide a new revenue figure for the nine months that would allow a like-for-like comparison for the full period.

The company also faced a disruption in supplies of thrombin, an ingredient used in Aurix. It said Pfizer is its sole supplier and that the ingredient was on back order by the third quarter of 2026. Nuo estimated that supplies would resume in the second quarter of 2027, after Aurix was temporarily out of stock for about two weeks in early August 2026. On reimbursement, the company said the 2026 national average reimbursement rate from the Centers for Medicare & Medicaid Services for Aurix treatment was $2,108 per session in hospital outpatient departments and $1,064 in private clinics. The proposed 2027 hospital rate was $2,360 per session. Under the terms of its secured notes, equal quarterly cash principal payments are due to begin on March 31, 2027, and the notes mature on December 31, 2028.

Open on chart